JACOBS LEVY EQUITY MANAGEMENT, INC - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 180 filers reported holding BRIDGEBIO PHARMA INC in Q4 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.

Quarter-by-quarter ownership
JACOBS LEVY EQUITY MANAGEMENT, INC ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q4 2022$9,784,004
-18.0%
1,283,990
+7.0%
0.07%
-29.8%
Q3 2022$11,929,000
+1830.3%
1,200,078
+1662.6%
0.09%
+1780.0%
Q2 2022$618,000
+204.4%
68,085
+1155.7%
0.01%
+150.0%
Q3 2020$203,000
-61.0%
5,422
-66.1%
0.00%
-66.7%
Q2 2020$521,00015,9880.01%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q4 2022
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$160,016,45665.94%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$819,077,80528.79%
Cormorant Asset Management, LP 4,662,530$122,950,9167.17%
Frazier Life Sciences Management, L.P. 2,725,949$71,883,2754.77%
Octagon Capital Advisors LP 971,639$25,622,1203.94%
M28 Capital Management LP 121,200$3,196,0443.66%
VIKING GLOBAL INVESTORS LP 25,120,991$662,440,5332.69%
BOONE CAPITAL MANAGEMENT LLC 313,381$8,263,8572.61%
Fernwood Investment Management, LLC 235,620$6,213,2992.23%
SOUTHPORT MANAGEMENT, L.L.C. 15,000$395,5502.15%
View complete list of BRIDGEBIO PHARMA INC shareholders